Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. (linkinghub.elsevier.com)

Authors: Giovannoni G … Oh J Journal: The Lancet Published: 2026-05-30 DOI: https://doi.org/10.1016/S0140-6736(26)00617-3